The FDA and CDC expect new formulations of COVID‑19 vaccines for the 2026–27 respiratory season. These updates are designed to match currently circulating variants, which continue to evolve faster than flu strains. The JAMA (The Journal of the American Medical Association) notes that COVID‑19 remains a year‑round threat, with seasonal surges similar to influenza but more unpredictable. JAMA noted: - SARS‑CoV‑2 mutates more quickly than influenza - Variant‑specific vaccines improve protection - Updated vaccines reduce severe disease, hospitalization, and long COVID risk The upcoming season will emphasize vaccination for: - Adults 65+ - People with chronic medical conditions - Pregnant individuals - Immunocompromised people Healthcare workers These groups continue to experience the highest hospitalization and death rates. Manufacturers are preparing monovalent vaccines targeting the most dominant strain, similar to the flu model.